Literature DB >> 19057516

Evaluation of asymmetric dimethylarginine and homocysteine in microangiopathy-related cerebral damage.

Yoshitomo Notsu1, Toru Nabika, Hirokazu Bokura, Yoji Suyama, Shotai Kobayashi, Schuhei Yamaguchi, Junichi Masuda.   

Abstract

BACKGROUND: Microangiopathy-related cerebral damage (MARCD) is an entity of cerebrovascular disease based on arteriosclerosis in deep white matter, which includes lacunar infarction and white matter hyperintensity (WMH). As asymmetric dimethylarginine (ADMA), an endogenous inhibitor of the nitric oxide (NO) synthases, and homocysteine are both potential risk factors for arteriosclerosis, the plasma levels of these two substances were evaluated in individuals with MARCD.
METHODS: Consecutive participants of a health examination (401 males and 311 females) were recruited for this cross-sectional study. All participants received an magnetic resonance imaging examination, and those with either lacunar infarction or WMH (grade > or =2) were classified into MARCD (+) (N = 146). The plasma ADMA concentration was measured with high performance liquid chromatography. The total homocysteine (tHcy) concentration was measured using a commercial kit.
RESULTS: The ADMA level (P < 0.001), symmetric dimethylarginine (SDMA) level (P < 0.05) and L-arginine (Arg)/ADMA ratio (P < 0.01) differed significantly between MARCD (+) and (-) according to nonparametric Wilcoxon test, while the tHcy level did not (P = 0.37). Classic risk factors such as age, blood pressure, and the presence of hypertension differed significantly between the two groups as well. In the logistic analysis, the association of Arg/ADMA with MARCD remained significant (odds ratio and 95% confidence interval, 0.19 (0.05, 0.73), P < 0.05) even after adjusting for the effects of age and hypertension.
CONCLUSIONS: ADMA and tHcy levels were studied in 712 subjects with or without MARCD. The Arg/ADMA ratio was suggested to be an independent risk factor for MARCD. A large-scale prospective study is warranted to confirm the causal relationship between Arg/ADMA and MARCD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19057516     DOI: 10.1038/ajh.2008.346

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  13 in total

Review 1.  Circulating biologic markers of endothelial dysfunction in cerebral small vessel disease: A review.

Authors:  Anna Poggesi; Marco Pasi; Francesca Pescini; Leonardo Pantoni; Domenico Inzitari
Journal:  J Cereb Blood Flow Metab       Date:  2016-01       Impact factor: 6.200

Review 2.  The pathobiology of vascular dementia.

Authors:  Costantino Iadecola
Journal:  Neuron       Date:  2013-11-20       Impact factor: 17.173

Review 3.  Increased circulatory asymmetric dimethylarginine and multiple organ failure: bile duct ligation in rat as a model.

Authors:  Jiunn-Ming Sheen; Yu-Chieh Chen; You-Lin Tain; Li-Tung Huang
Journal:  Int J Mol Sci       Date:  2014-03-05       Impact factor: 5.923

4.  Resting brain perfusion and selected vascular risk factors in healthy elderly subjects.

Authors:  Otto M Henriksen; Lars T Jensen; Katja Krabbe; Per Guldberg; Tom Teerlink; Egill Rostrup
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.240

5.  The transporter and permeability interactions of asymmetric dimethylarginine (ADMA) and L-arginine with the human blood-brain barrier in vitro.

Authors:  Christopher P Watson; Evangelos Pazarentzos; Mehmet Fidanboylu; Beatriz Padilla; Rachel Brown; Sarah A Thomas
Journal:  Brain Res       Date:  2016-07-16       Impact factor: 3.252

6.  Cerebral Small Vessel Disease: A Review Focusing on Pathophysiology, Biomarkers, and Machine Learning Strategies.

Authors:  Elisa Cuadrado-Godia; Pratistha Dwivedi; Sanjiv Sharma; Angel Ois Santiago; Jaume Roquer Gonzalez; Mercedes Balcells; John Laird; Monika Turk; Harman S Suri; Andrew Nicolaides; Luca Saba; Narendra N Khanna; Jasjit S Suri
Journal:  J Stroke       Date:  2018-09-30       Impact factor: 6.967

Review 7.  Asymmetric dimethyarginine as marker and mediator in ischemic stroke.

Authors:  Shufen Chen; Na Li; Milani Deb-Chatterji; Qiang Dong; Jan T Kielstein; Karin Weissenborn; Hans Worthmann
Journal:  Int J Mol Sci       Date:  2012-11-28       Impact factor: 5.923

Review 8.  Asymmetric dimethylarginine, endothelial dysfunction and renal disease.

Authors:  Luis Aldámiz-Echevarría; Fernando Andrade
Journal:  Int J Mol Sci       Date:  2012-09-10       Impact factor: 6.208

9.  Melatonin prevented spatial deficits and increases in brain asymmetric dimethylarginine in young bile duct ligation rats.

Authors:  Mei-Hsin Hsu; Yu-Chieh Chen; Jiunn-Ming Sheen; Shih-Wen Li; Li-Tung Huang
Journal:  Neuroreport       Date:  2018-05-02       Impact factor: 1.837

10.  Endothelial Dysfunction May Link Interatrial Septal Abnormalities and MTHFR-Inherited Defects to Cryptogenic Stroke Predisposition.

Authors:  Luca Sgarra; Alessandro Santo Bortone; Maria Assunta Potenza; Carmela Nacci; Maria Antonietta De Salvia; Tommaso Acquaviva; Emanuela De Cillis; Marco Matteo Ciccone; Massimo Grimaldi; Monica Montagnani
Journal:  Biomolecules       Date:  2020-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.